Moreover, high expression of cdc7 and RNA polymerase II Subunit A (POLR2A), the direct target of CDK9, is significantly correlated with poor metastasis-free survival in a cohort of breast cancer patients.
The functional polymorphism on <i>CDC7,</i> rs13447455, influences <i>CDC7</i> transcriptional activity in an allele-specific manner and alters DNA⁻protein complex formation in breast cancer cell lines.
Emerging Cdc7 kinase inhibitors may therefore significantly broaden the therapeutic armamentarium for treatment of the aggressive p53-mutant breast cancer subtypes identified in this study.